BRSYF
Brainsway Ltd.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 15 ▲ Brainsway highlighted expanding U.S. payer coverage allowing nurse p…
- Apr 20 ▲ Brainsway's 20-F filing for 2025 shows strong financial growth with…
- May 13 ▲ BrainsWay reported Q1 2026 revenue of $15.5 million (up 35% YoY) and…
- Jun 9 ▲ BrainsWay presented new 12-month durability data for its SWIFT accel…
- Aug 14 ▼ Short interest jumps 1809.8% to 28.6K
- Aug 31 ▲ Short interest falls 95.5% to 1.3K
Signal stack
Where each data set points today.
- Short sellersSTEADY
Short interest 0.0% to 1.4K shares. 8.5 days to cover.
- TrendDOWNTREND
18% below its 50-day average.
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | None | None | No data | $69.8M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
5 filings · 4 bullish · 0 bearish · 1 neutral- BULLISH 6-KJun 9, 2026
BrainsWay presented new 12-month durability data for its SWIFT accelerated Deep TMS protocol at…
The durability data significantly strengthens BrainsWay's competitive position in the TMS market, potentially accelerating adoption by providers and supporting reimbursement discussions. Traders…
- NEUTRAL 6-KMay 18, 2026
BrainsWay announced a minority-stake investment of $1.5 million (with potential for an additional…
This is a routine strategic investment with no immediate earnings impact. Monitor for future milestone payments and any revenue contribution from Hopemark, but the near-term stock catalyst is…
- BULLISH 6-KMay 13, 2026
BrainsWay reported Q1 2026 revenue of $15.5 million (up 35% YoY) and net income of $2.3 million…
Strong Q1 beat across all metrics with reiterated guidance suggests accelerating momentum. Watch for FDA filing in Q2 2026 for PTSD indication, which could expand TAM. The $8.5 million in financial…
- BULLISH 20-FApr 20, 2026
Brainsway's 20-F filing for 2025 shows strong financial growth with a 27% revenue increase to…
Monitor the resolution of the Magnus Medical patent dispute, as an unfavorable outcome could impact the commercialization of the newly cleared accelerated treatment protocol. The company's heavy…
All BRSYF filing & press-release reports (5)
- 6-K reportJun 9, 2026
- 6-K reportMay 18, 2026
- 6-K reportMay 13, 2026
- 20-F reportApr 20, 2026
- 6-K reportApr 15, 2026